Utilizing meta-analysis of tumor marker blood test kinetics in ovarian cancer patients

Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more reliable prognostic marker.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup